Pulse Explore Journal Club Debates Trending Researchers Journals

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia | Synapse

March 11, 202629 citations

View Full Paper

An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia

MKMichael Koren RVRick B. Vega NANikhil Agrawal

Key Points

Reduction in cholesterol levels observed with the oral PCSK9 inhibitor, showing promising results for hypercholesterolemia treatment.
Key measure of efficacy demonstrated a significant improvement in lipid profiles over standard treatments.
Assessment utilized advanced lipid management protocols to evaluate treatment effectiveness and patient response.
Potential to broaden treatment options for hypercholesterolemia, addressing a gap in current therapeutic strategies.

Abstract

An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia

Ask AI

Helpful

Bookmark

Share

View Full Paper

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Koren et al. (Wed,) studied this question.

synapsesocial.com/papers/69b19b8dd8cfb334e198cc18 https://doi.org/10.1016/j.jacc.2025.03.499